Skip to main content

Table 5 Clinical validity EORTC QLQ-C30 and QLQ-BR23 Amharic version in women with breast cancer in Ethiopia (n = 146)

From: Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia

Quality of life score: mean(SD)

 

EORTC-QLQ-C30

Baseline

End of 1st CTb cycle

p-value

Overall QoL

Global Health status

57.36(20.09)

41.72(19.24)

0.000

Physical

68.63(26.06)

51.00(23.70)

0.000

Role

52.74(38.85)

23.74(31.37)

0.000

Functional scales

Emotional

80.02(22.60)

67.81(25.14)

0.000

Cognitive

86.41(19.96)

77.39(26.31)

0.000

Social

74.88(30.59)

58.22(33.11)

0.000

Fatigue

28.69(30.40)

72.07(26.10)

0.000

Symptoms scales

Nausea and Vomiting

3.31(11.84)

53.53(34.19)

0.000

Pain

32.53(30.53)

42.00(33.11)

0.001

Dyspnea

19.40(29.75)

28.76(29.97)

0.003

Insomnia

27.85(34.58)

35.61(37.88)

0.024

Single items

Appetite loss

17.80(29.59)

71.23(31.22)

0.000

Constipation

10.27(21.99)

22.83(31.74)

0.000

Diarrhea

2.74(12.07)

16.89(30.38)

0.000

Financial problem

61.18(36.72)

65.52(33.77)

0.000

EORTC-QLQ-BR23

 Functional scales

Body Image

72.54(42.45)

72.60(27.24)

0.985

Sexual Functioning

21.11(36.95)

12.21(28.72)

0.004

Therapya side effects

12.88(15.08)

50.71(19.70)

0.000

 Symptoms scale

Breast symptoms

22.48(22.34)

17.63(19.94)

0.000

Arm symptoms

26.03(26.08)

18.79(23.18)

0.000

 Single items

Future perspectives

69.63(33.43)

63.69(35.21)

0.041

Sexual Enjoyment

72.91(32.70)

70.83(34.15)

0.817

  1. aSystemic therapy side effects
  2. bAfter three weeks, on 21st day of the CT (Chemotherapy) or on the first day of 2nd cycle CT.
  3. SD Standard Deviation, QoL Quality of Life